Americans suffering from a deadly form of brain cancer have new hope today, thanks to a first-of-its-kind treatment program offered under the federal Right to Try law—a policy developed by the Goldwater Institute.
An anti-cancer vaccine known as Gliovac (ERC1671) will be made available to patients suffering from glioblastoma, a rare and fatal cancer with a devastating five-year survival rate of about five percent. Since the treatment has not received final approval by the U.S. Food and Drug Administration (FDA), patients ordinarily would not be able to access the potentially lifesaving vaccine without being selected for a clinical trial or making a request through the FDA’s burdensome and time-consuming “compassionate use” program. However, thanks to the recently enacted federal Right to Try law, Epitopoietic Research Corporation (ERC), the vaccine’s manufacturer, has announced a program offering Gliovac to patients who meet certain eligibility requirements.
Under Right to Try, a policy developed by the Goldwater Institute, patients who are terminal or facing life-threatening illness and who have exhausted other treatment options may, with their physician’s approval, seek investigational treatments that are safe enough to be used in clinical trials but remain under clinical evaluation for final FDA approval. As Goldwater Director of Healthcare Policy Naomi Lopez Bauman writes in a new In Defense of Liberty blog post, ERC’s announcement of a formal Right to Try program is “not only great news for terminal patients—it also points to a more positive future for treatment innovations.”
|